Dengue

Infectious Diseases
13
Pipeline Programs
8
Companies
25
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
2
5
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
3100%
+ 14 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
5 programs
3
1
Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virusPhase 31 trial
CYD Dengue VaccinePhase 2Vaccine5 trials
Chimeric dengue serotypePhase 21 trial
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virusPhase 21 trial
Dengue Effectiveness Study in the PhilippinesN/A1 trial
Active Trials
NCT03803618Completed2,081Est. Apr 2023
NCT04113330Active Not Recruiting918Est. Jul 2028
NCT02993757Completed528Est. May 2019
+6 more trials
M&
Merck & Co.RAHWAY, NJ
3 programs
1
1
V181Phase 21 trial
V180Phase 12 trials
Dengue Immunoglobulin G antibodies performed with ELISAN/A1 trial
Active Trials
NCT05919277Unknown1,487Est. Sep 2024
NCT02450838Completed20Est. Oct 2015
NCT01477580Completed98Est. Dec 2014
+1 more trials
Medigen Vaccine Biologics
1 program
1
TV003Phase 21 trial
Active Trials
NCT03485144CompletedEst. May 2019
GSK
GSKLONDON, United Kingdom
3 programs
2
DEN vaccine F17Phase 1/2Vaccine1 trial
Tetravalent live attenuated dengue vaccinePhase 1/2Vaccine1 trial
Data collectionN/A1 trial
Active Trials
NCT01391819Completed2,117Est. Jan 2015
NCT01843621Completed7Est. Feb 2009
NCT00322049Completed51Est. Jun 2009
Atea Pharmaceuticals
2 programs
2
AT-752Phase 11 trial
AT-752Phase 11 trial
Active Trials
NCT05366439TerminatedEst. Mar 2023
NCT04722627CompletedEst. Nov 2021
Gylden Pharma
Gylden PharmaUK - Abingdon
1 program
1
LD vehicle-GNPPhase 11 trial
Active Trials
NCT04935801Completed26Est. Sep 2022
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
TV005Phase 11 trial
Active Trials
NCT02317900Completed
Abbott
AbbottABBOTT PARK, IL
1 program
Dengue - Sample Collection Study PakistanN/A1 trial
Active Trials
NCT07203183Not Yet Recruiting200Est. Apr 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
SanofiCYD Dengue Vaccine
SanofiCYD Dengue Vaccine
SanofiLive, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus
Merck & Co.V181
Medigen Vaccine BiologicsTV003
SanofiCYD Dengue Vaccine
SanofiLive, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
SanofiCYD Dengue Vaccine
SanofiCYD Dengue Vaccine
SanofiCYD Dengue Vaccine
SanofiCYD Dengue Vaccine
SanofiChimeric dengue serotype
GSKDEN vaccine F17
GSKTetravalent live attenuated dengue vaccine
Atea PharmaceuticalsAT-752

Showing 15 of 25 trials with date data

Clinical Trials (25)

Total enrollment: 12,970 patients across 25 trials

NCT02993757SanofiCYD Dengue Vaccine

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Start: Dec 2016Est. completion: May 2019528 patients
Phase 3Completed
NCT02979535SanofiCYD Dengue Vaccine

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Start: Nov 2016Est. completion: Mar 2019480 patients
Phase 3Completed
NCT01411241SanofiLive, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Start: Jul 2011Est. completion: Apr 2014720 patients
Phase 3Completed
NCT05710224Merck & Co.V181

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)

Start: Feb 2023Est. completion: Dec 20241,364 patients
Phase 2Completed
NCT03485144Medigen Vaccine BiologicsTV003

A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan

Start: Dec 2017Est. completion: May 2019
Phase 2Completed
NCT01943825SanofiCYD Dengue Vaccine

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Start: Nov 2013Est. completion: Nov 201590 patients
Phase 2Completed
NCT01488890SanofiLive, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Start: Dec 2011Est. completion: Sep 2013390 patients
Phase 2Completed
NCT00993447SanofiCYD Dengue Vaccine

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Start: Oct 2009Est. completion: Mar 2012600 patients
Phase 2Completed
NCT00880893SanofiCYD Dengue Vaccine

Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Start: Apr 2009Est. completion: Oct 20141,198 patients
Phase 2Completed
NCT00788151SanofiCYD Dengue Vaccine

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Start: Sep 2008Est. completion: Aug 2010300 patients
Phase 2Completed
NCT00617344SanofiCYD Dengue Vaccine

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Start: Apr 2008Est. completion: Feb 2010260 patients
Phase 2Completed
NCT00730288SanofiChimeric dengue serotype

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Start: Aug 2006Est. completion: Jan 200835 patients
Phase 2Completed
NCT01843621GSKDEN vaccine F17

A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children

Start: Feb 2005Est. completion: Feb 20097 patients
Phase 1/2Completed
NCT00322049GSKTetravalent live attenuated dengue vaccine

A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants

Start: Feb 2004Est. completion: Jun 200951 patients
Phase 1/2Completed
NCT05366439Atea PharmaceuticalsAT-752

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

Start: Apr 2022Est. completion: Mar 2023
Phase 1Terminated
NCT04935801Gylden PharmaLD vehicle-GNP

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus

Start: Aug 2021Est. completion: Sep 202226 patients
Phase 1Completed
NCT04722627Atea PharmaceuticalsAT-752

Study of AT-752 in Healthy Subjects

Start: Mar 2021Est. completion: Nov 2021
Phase 1Completed
NCT02450838Merck & Co.V180

Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)

Start: Apr 2015Est. completion: Oct 201520 patients
Phase 1Completed
NCT02317900Allergy TherapeuticsTV005

Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults

Start: Dec 2014
Phase 1Completed
NCT01477580Merck & Co.V180

Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)

Start: Jul 2012Est. completion: Dec 201498 patients
Phase 1Completed
NCT07203183AbbottDengue - Sample Collection Study Pakistan

Dengue - Sample Collection Study Pakistan

Start: Oct 2025Est. completion: Apr 2026200 patients
N/ANot Yet Recruiting
NCT05919277Merck & Co.Dengue Immunoglobulin G antibodies performed with ELISA

A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires

Start: Sep 2023Est. completion: Sep 20241,487 patients
N/AUnknown
NCT04113330SanofiCYD Dengue Vaccine

Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia

Start: Jan 2020Est. completion: Jul 2028918 patients
N/AActive Not Recruiting
NCT03803618SanofiDengue Effectiveness Study in the Philippines

Dengue Effectiveness Study in the Philippines

Start: Sep 2017Est. completion: Apr 20232,081 patients
N/ACompleted
NCT01391819GSKData collection

Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children

Start: Sep 2011Est. completion: Jan 20152,117 patients
N/ACompleted

Related Jobs in Infectious Diseases

Senior Recruiter

Invivyd
New Haven, CT (Northeast preferred)
10h ago
$120K - $160K/yr

Senior Associate Scientist (contract), Upstream Polysaccharide Process Development

VaxCyte
San Carlos, California, United States
12h ago
$56/hr

Senior Associate Scientist (contract), Polysaccharide Analytical Development

VaxCyte
San Carlos, California, United States
12h ago
$56/hr

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
16h ago
$179K - $237K/yr

Technician, Operations, DSP/ Technicien(ne) des opérations, DSP

Verona Pharma
CAN - Prince Edward Island - Charlottetown
Yesterday
$47K - $79K/yr

HVAC Maintenance Technician

Verona Pharma
USA - Delaware - Millsboro (Intervet)
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
8 companies competing in this space

Related Indications

HIV Infections(576)Influenza(314)COVID-19(229)Hepatitis C(201)HIV(178)Hepatitis B(148)HIV-1-infection(137)HIV Infection(108)Chronic Hepatitis B(103)Hepatitis C, Chronic(96)